OPTIMISING COLORECTAL CANCER PREVENTION TROUGH PERSONALISED TREATMENT WITH ARTIFICIAL INTELLIGENCE

通过人工智能的个性化治疗优化结直肠癌的预防

• 批准号: 10072975
• 金额: $ 43.92万
• 依托单位: KING'S COLLEGE HOSPITAL NHS FOUNDN TRUST
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072975
• 关键词: OPTIMISING; COLORECTAL; CANCER; PREVENTION; TROUGH

ntegration of artificial intelligence (AI) technologies into clinical medicine has been hampered by challenges related to uncertain long term clinical benefits, cost-effectiveness, and ethics/legal concerns. Application of AI in colonoscopy, a forefront research topic, has been also bothered by these issues. AI is, however, expected to reduce colorectal cancer incidence and mortality through personalised treatment. Our proposed project would change this discouraging situation and thus drastically improves colorectal cancer care. We achieve the following goals: 1. Establish the value of AI-assisted colonoscopy in colorectal cancer prevention by conducting a pan-European, population-based, randomised trial with 222,000 participants. 2. Develop a colonoscopy AI risk-prediction tool for personalized treatment of colorectal polyps and cancer. 3. Develop cost-effectiveness models of AI-assisted colonoscopy in colorectal cancer screening. 4. Investigate ethical and legal barriers in AI development and implementation. 5. Generate the first trustworthy and rapidly updating (? living?) clinical guidelines for AI in screening colonoscopy. 6. Develop a patient-oriented AI tool by including end-users in the process of AI development and communication. Our research consortium maximises the feasibility of the project, with world-class experts in gastroenterology, machine learning, cancer screening, biostatistics, disease modelling, regulatory science, and ethics and law in medicine from nine European countries, the US and Japan. We also partner with a European medium-size AI enterprise for implementing the output of the project. The project has large potential impact on patients, society, and economy in Europe, and the World. Up to 6,000 fewer deaths due to colorectal cancer and saving of 720 million euro can be expected per year once the technology is widely accepted in Europe

人工智能（AI）技术与临床医学的整合受到与不确定的长期临床益处、成本效益和伦理/法律的关注相关的挑战的阻碍。人工智能在结肠镜检查中的应用是一个前沿研究课题，也一直受到这些问题的困扰。然而，AI有望通过个性化治疗降低结直肠癌的发病率和死亡率。我们提出的项目将改变这种令人沮丧的情况，从而大大改善结直肠癌的护理。我们实现了以下目标：1.通过对222，000名参与者进行一项泛欧、基于人群的随机试验，确定AI辅助结肠镜检查在预防结直肠癌中的价值。2.开发结肠镜AI风险预测工具，用于结肠直肠息肉和癌症的个性化治疗。3.开发AI辅助结肠镜检查在结直肠癌筛查中的成本效益模型。4.调查人工智能开发和实施中的道德和法律的障碍。5.生成第一个值得信赖和快速更新的（？生活？）结肠镜检查中AI的临床指南。6.通过将最终用户纳入AI开发和通信过程，开发面向患者的AI工具。我们的研究联盟最大限度地提高了该项目的可行性，与来自九个欧洲国家，美国和日本的胃肠病学，机器学习，癌症筛查，生物统计学，疾病建模，监管科学以及医学伦理和法律方面的世界级专家。我们还与一家欧洲中型人工智能企业合作，实施该项目的产出。该项目对欧洲和世界的患者、社会和经济具有巨大的潜在影响。一旦该技术在欧洲被广泛接受，预计每年可减少多达6，000例结直肠癌死亡，并节省7.2亿欧元